Skip to main content
Premium Trial:

Request an Annual Quote

PerkinElmer Announces Purchase Price for Notes

NEW YORK, Nov. 9 (GenomeWeb News) - PerkinElmer disclosed the purchase price for its previously announced tender offer after markets closed yesterday.

 

As GenomeWeb News reported yesterday afternoon, PerkinElmer received consents from its noteholders approving its cash tender offer for outstanding notes.

 

PerkinElmer anticipates Nov. 14 as the initial settlement date.

 

Holders who tender notes prior to the settlement date will receive total consideration per $1,000 principal amount of notes tendered of $1,119.64. This includes the consent payment of $20 and accrued and unpaid interest up to the payment date.

 

Holders who tender notes between the settlement date and expiration date of Nov.23, 9:00am, will receive total consideration per $1,000 principal amount of notes tendered of $1,118.65. This also includes the consent payment and accrued and unpaid interest.

 

The purchase price was calculated with the bid-side price of the US Treasury Note as indicated on Bloomberg screen PX5 at 2:00pm New York City time yesterday, the company said.

 

The company also said today that $269.9 million, or 99.6% of the aggregate outstanding principal amount of notes was validly tendered. The company had said 96% yesterday.

The Scan

New Study Highlights Role of Genetics in ADHD

Researchers report in Nature Genetics on differences in genetic architecture between ADHD affecting children versus ADHD that persists into adulthood or is diagnosed in adults.

Study Highlights Pitfall of Large Gene Panels in Clinical Genomic Analysis

An analysis in Genetics in Medicine finds that as gene panels get larger, there is an increased chance of uncovering benign candidate variants.

Single-Cell Atlas of Drosophila Embryogenesis

A new paper in Science presents a single-cell atlas of fruit fly embryonic development over time.

Phage Cocktail Holds Promise for IBD

Researchers uncovered a combination phage therapy that targets Klebsiella pneumonia strains among individuals experiencing inflammatory bowel disease flare ups, as they report in Cell.